

Announcements

(Requests for announcements must be received at least three months before publication.)

1998 ANNUAL MEETING

The AACR's Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in New Orleans, LA, March 28–April 1, 1998. The Chairperson of the Annual Meeting is Frank J. Rauscher III of the Wistar Institute. The Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, controversy sessions, and meet-the-expert sunrise sessions. They also look forward to receiving for consideration for presentation the proffered papers submitted by members of the cancer research community. All abstracts must be sponsored by an AACR member in good standing.

FUTURE ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

1998 March 28–April 1, New Orleans, LA
1999 April 10–14, Philadelphia, PA

CALL FOR NOMINATIONS FOR AACR AWARDS

The AACR presents six awards to distinguished scientists at its Annual Meeting. The Awards Committee, consisting of six separate subsections, will recommend candidates for each award to the AACR Executive Committee. Below you will find a description of each award. Members wishing to make nominations should provide a short description of the candidate's accomplishments; the subcommittee involved will obtain further documentation on suitable candidates. Nominations may be directed to the Association Office for forwarding to the appropriate subcommittee. This material should be received no later than September 15, 1997.

Clowes Memorial Award. The Eli Lilly Company established the Clowes Memorial Lecture to honor Dr. G. H. A. Clowes, who was a founding member of the AACR and a research director of Eli Lilly. The purpose of the award is to give "recognition of outstanding research accomplished in some recent period." The Clowes Award should recognize outstanding recent accomplishments in basic cancer research, and the Board of Directors construes this to mean both laboratory research and epidemiological investigations.

Joseph H. Burchenal AACR Clinical Research Award. Bristol-Myers Squibb has established this award to recognize outstanding achievements in clinical cancer research. It is named for Dr. Joseph H. Burchenal, past president and honorary member of the AACR, and a leading figure in the field of cancer chemotherapy. There are no restrictions on the age or geographic location of the awardee.

Richard and Hinda Rosenthal Foundation Award. The Rosenthal Foundation has established this award to "recognize research which has made or gives the promise of soon making a notable contribution to improved clinical care in the field of cancer." The Foundation wishes to honor and provide incentive to young investigators relatively early in their careers. It has, therefore, stipulated that the Association restrict the award to individuals who are engaged in the practice of medicine, who reside in the Americas, and who will not be more than 50 years of age at the time of the award (March 1998).

Rhoads Memorial Award. In 1979, an anonymous donor established this award in memory of Dr. Cornelius P. Rhoads, a founder and the first Director of the Sloan-Kettering Institute for Cancer Research. This annual award is intended to give recognition to an "individual on the basis of meritorious achievement in cancer research." In accordance with the donor's wishes, the awardee must be a young investigator; therefore, the Board of Directors of the Association has stipulated that the recipient must not have reached his or her 41st birthday by the time of the award (March 1998).

Cain Memorial Award. The Warner-Lambert Company instituted this award to honor the memory of Dr. Bruce F. Cain of New Zealand for his work in the "design, synthesis, and biological evaluation of potential anticancer drugs." The purpose of the award is to "give recognition to an individual or

research team for outstanding preclinical research that has implications for the improved care of cancer patients." Examples of such research include discovery of a significant new anticancer agent and major contributions to a compound's application as an antitumor agent. The award will recognize outstanding contributions in the fields of medicinal chemistry, biochemistry, or tumor biology as related to drug discovery; will encompass anticancer, antiviral, and antifungal agents; will have no age limit; and will be international in scope.

American Cancer Society Award. The American Cancer Society sponsors this award to honor outstanding achievements in the fields of epidemiology, biomarkers, and prevention. There are no age or geographical restrictions on the awardee.

AACR SPECIAL CONFERENCES IN CANCER RESEARCH

A number of meetings are now being organized in the AACR's series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 826, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR's website (<http://www.aacr.org/confnrc.html>).

CANCER OF THE CENTRAL NERVOUS SYSTEM (Joint Meeting with Neurosurgery Joint Section on Tumors)

June 7–11, 1997

Loew's Coronado Bay Resort, San Diego, CA

Chairpersons

Peter McL. Black, Boston, MA
Webster K. Cavenee, La Jolla, CA

MOLECULAR GENETICS OF CANCER

Joint Meeting with European Association for Cancer Research
September 9–13, 1997

Hertford College, Oxford, United Kingdom

Chairpersons

Eric J. Stanbridge, Irvine, CA
Walter Bodmer, Oxford, United Kingdom

TUMOR SUPPRESSOR GENES

Co-sponsored by the National Cancer Institute of Canada
September 26–30, 1997

Victoria Conference Centre, Victoria, BC, Canada

Chairpersons

Stephen H. Friend, Seattle, WA
Philip Branton, Montreal, Quebec, Canada

**TRANSCRIPTIONAL CONTROL OF PROLIFERATION,
DIFFERENTIATION, AND DEVELOPMENT**

October 17–21, 1997

The Sagamore Resort, Bolton Landing (Lake George), NY

ChairpersonsRobert Eisenman, Seattle, WA
Elaine V. Fuchs, Chicago, IL**DNA METHYLATION IMPRINTING, AND THE EPIGENETICS
OF CANCER**

December 12–16, 1997

El Conquistador Resort and Country Club, Las Croabas, PR

ChairpersonsPeter A. Jones, Los Angeles, CA
Stephen B. Baylin, Baltimore, MD
Timothy Bestor, New York, NY**PROGRAMMED CELL DEATH**

January 9–13, 1998

Renaissance Esmeralda Resort, Palm Springs, CA

ChairpersonsJohn C. Reed, La Jolla, CA
Vishva M. Dixit, Ann Arbor, MI**ANGIOGENESIS AND CANCER**

January 24–28, 1998

Hyatt Orlando, Orlando, FL

ChairpersonsJudah Folkman, Boston, MA
Michael Klagsbrun, Boston, MA**INNOVATIVE MOLECULAR BIOLOGY APPROACHES TO THE
PREVENTION, DIAGNOSIS, AND THERAPY OF CANCER**

Joint Meeting with the Japanese Cancer Association

February 16–21, 1998

Maui Marriott Hotel, Maui, HI

ChairpersonsEdward Bresnick, Worcester, MA
Kaoru Abe, Tokyo, Japan**CALENDAR OF EVENTS**

Gene Transcription-based Drugs, June 2–3, 1997, Washington, DC. Contact: Cambridge Healthtech Institute, 1037 Chestnut Street, Newton Upper Falls, MA 02164. Phone: (617) 630-1300; Fax: (617) 630-1325; E-mail: chi@healthtech.com.

In Vitro Toxicology: Techniques and Applications, originally scheduled for June 3–6, 1997. Postponed until 1998. Contact: ATCC, Workshop Coordinator, 12301 Parklawn Drive, Rockville, MD 20852. Phone (800) 359-7370; Fax: (301) 816-4364; E-mail: workshops@atcc.org.

Advances in Labels, Signaling and Detection: Improving Sensitivity, Accuracy, and Speed, June 5–6, 1997, San Diego, CA. Contact: Cambridge Healthtech Institute, 1037 Chestnut Street, Newton Upper Falls, MA 02164. Phone: (617) 630-1300; Fax: (617) 630-1325; E-mail: chi@healthtech.com.

Gene Detection and Quantification for Infectious Agents and Human Genetic Diseases, June 9–11, 1997, San Diego Hilton Beach and Tennis Resort, San Diego, CA. Contact: IBC USA Conferences, Inc., 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: reg@ibcusa.com.

General Motors Cancer Research Foundation Annual Conference, "Cutaneous Malignancies," June 10–11, 1997, Jack Masur Auditorium, National Institutes of Health, Bethesda, MD. Contact: General Motors Cancer Research Foundation, c/o Campbell, Peachey, & Associates, 111 Quincy Place, NE, Washington, DC 20002. Phone: (202) 636-8745; Fax: (202) 636-8755.

Beyond the Human Genome Project: From Genes to Proteins, June 13–14, 1997, San Francisco, CA. Contact: Cambridge Healthtech Institute, 1037 Chestnut Street, Newton Upper Falls, MA 02164. Phone: (617) 630-1300; Fax: (617) 630-1325; E-mail: chi@healthtech.com.

Second Biennial Cancer Vaccines, June 16–17, 1997, Washington, DC. Contact: Cambridge Healthtech Institute, 1037 Chestnut Street, Newton Upper Falls, MA 02164. Phone: (617) 630-1300; Fax: (617) 630-1325; E-mail: chi@healthtech.com.

Fifth Annual Gene Amplification and Detection: Technology and Applications, June 16–17, 1997, San Francisco, CA. Contact: Cambridge Healthtech Institute, 1037 Chestnut Street, Newton Upper Falls, MA 02164. Phone: (617) 630-1300; Fax: (617) 630-1325; E-mail: chi@healthtech.com.

Third Conference on Hematopoietic Stem Cells, June 23–24, 1997, Wyndham Emerald Plaza Hotel, San Diego, CA. Contact: IBC USA Conferences, Inc., 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: reg@ibcusa.com.

Third International Symposium on Endothelin Inhibitors, Advances in Therapeutic Application and Development, June 26–27, 1997, The Doubletree Hotel, Philadelphia, PA. Contact: IBC USA Conferences, Inc., 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: reg@ibcusa.com.

Breast Cancer, Developing a Multi-Disciplinary Continuum of Care, June 26–27, 1997, Swissotel, Boston, MA. Contact: IBC USA Conferences, Inc., 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: reg@ibcusa.com.

Seventeenth International Symposium on Cancer sponsored by the Sapporo Cancer Seminar Foundation, "Cytoskeleton and G Proteins in the Regulation of Cancer," July 8–10, 1997, Centennial Hall, Hokkaido University, Sapporo, Hokkaido, Japan. Contact: Dr. Noboru Kuzumaki, 17th International Symposium on Cancer, Laboratory of Gene Regulation, Cancer Institute, Hokkaido University School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060, Japan. Phone: (81) 11-716-2111; Fax: (81) 11-706-7869; E-mail: kuzumaki@med.hokudai.ac.jp.

Strategies for Regulating Growth Factors, Advances in Therapeutic Application and Development, July 14–15, 1997, Boston Park Plaza Hotel, Boston, MA. Contact: IBC USA Conferences, Inc., 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: reg@ibcusa.com.

Advances in Imaging for Drug Development and Discovery, July 14–15, 1997, Boston Park Plaza Hotel, Boston, MA. Contact: IBC USA Conferences, Inc., 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: reg@ibcusa.com.

Tumor Suppressors and Oncogenes, Latest Discoveries for Novel Therapeutic Application, July 24–25, 1997, Fairmont Hotel, San Francisco, CA. Contact: IBC USA Conferences, Inc., 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: reg@ibcusa.com.

Nuclear Hormone Receptors, Targets for Therapeutic Intervention, July 28–29, 1997, The Ritz-Carlton, Philadelphia, PA. Contact: IBC USA Conferences, Inc., 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: reg@ibcusa.com.

Cell Culture and Hybridomas: Quality Control and Cryopreservation Techniques, September 8–10, 1997, Rockville, MD. Contact: ATCC, Workshop Coordinator, 12301 Parklawn Drive, Rockville, MD 20852. Phone: (800) 359-7370; Fax: (301) 816-4364; E-mail: workshops@atcc.org.

Fifteenth Annual ATCC Biotech Patent Forum, September 15–16, 1997, Rockville, MD. Contact: ATCC, Workshop Coordinator, 12301 Parklawn Drive, Rockville, MD 20852. Phone: (800) 359-7370; Fax: (301) 816-4364; E-mail: workshops@atcc.org.

Cytogenetic and Fluorescence *in Situ* Hybridization, September 17–19, 1997, Rockville, MD. Contact: ATCC, Workshop Coordinator, 12301 Parklawn Drive, Rockville, MD 20852. Phone: (800) 359-7370; Fax: (301) 816-4364; E-mail: workshops@atcc.org.

Gene Therapy in Cancer, September 27–30, 1997, Athens, Greece. Deadline for abstract submission: June 30, 1997. Contact: Dr. John G. Delinassios, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki 19014, Greece. Phone and Fax: (0030) 295-53389.

Apoptosis, October 2–5, 1997, Athens, Greece. Deadline for abstract submission: June 30, 1997. Contact: Dr. John G. Delinassios, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki 19014, Greece. Phone and Fax: (0030) 295-53389.

Hormones, Blood Cells, and Immunity, October 3–8, 1997, Obernai (Strasbourg), France. Deadline for applications: June 15, 1997. Contact: Dr. Josip Hendekovic, European Science Foundation, 1 quai Lezay-Marnesia, 67080 Strasbourg Cedex, France. Phone: (33) 3-88-76-71-35; Fax: (33) 3-88-36-69-87; E-mail: euresco@esf.org.

Hybridoma Technology and Monoclonal Antibody Product Development, October 6–9, 1997, Rockville, MD. Contact: ATCC, Workshop Coordinator, 12301 Parklawn Drive, Rockville, MD 20852. Phone: (800) 359-7370; Fax: (301) 816-4364; E-mail: workshops@atcc.org.

Invasion and Metastasis, October 7–10, 1997, Athens, Greece. Deadline for abstract submission: June 30, 1997. Contact: Dr. John G. Delinassios, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki 19014, Greece. Phone and Fax: (0030) 295-53389.

New Anticancer Agents, October 12–15, 1997, Athens, Greece. Deadline for abstract submission: June 30, 1997. Contact: Dr. John G. Delinassios, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki 19014, Greece. Phone and Fax: (0030) 295-53389.

Eighth Conference on DNA Topoisomerases in Therapy, October 15–17, 1997, Amsterdam, the Netherlands. Contact: The European Cancer Centre, P.O. Box 7057, NL-1007 MB Amsterdam, the Netherlands. Phone: 31 (0)20 644-4500; Fax: 31 (0)20 644-4551; E-mail: ecc@euronet.nl.

Correction

Recently, it was brought to our attention that in our paper entitled “Transforming Growth Factor $\beta 1$ Suppresses Genomic Instability Independent of a G_1 Arrest, *p53*, and *Rb*” (Glick *et al.*, *Cancer Res.*, 56: 3645–3650, 1996), we incorrectly stated that Garrigue-Antar *et al.* (*Cancer Res.*, 55: 3982–3987, 1995) reported a mutation in the TGF- β type II receptor in the TGF- β -resistant FaDu human carcinoma cell line, when it is actually wild type. This misstatement does not alter the results of our study showing that FaDu cells do not respond to growth inhibition or suppression of PALA resistance by TGF- $\beta 1$. To determine the basis for nonresponsiveness to TGF- β , FaDu cells were transfected with the TGF- β response plasmid p800luc containing the PAI promoter (Abe *et al.*, *Anal. Biochem.*, 216: 276–284, 1994). TGF- $\beta 1$ caused a 3-fold induction of luciferase activity in the control H4 mouse keratinocyte cell line, whereas there was no induction in either the FaDu cell line or the HCT116 colon carcinoma cell line, which contains a mutated TGF- β type II receptor (Fig. 1). This indicates that the lack of responsiveness to TGF- $\beta 1$ in the FaDu cells is due to a defect in the TGF- $\beta 1$ signaling pathway rather than other alterations indirectly affecting growth regulation by TGF- $\beta 1$. Additionally, this suggests that the suppression of PALA resistance by TGF- $\beta 1$ is linked to the signaling pathway regulating gene expression. We thank Dr. Michael Reiss for drawing our attention to the status of the TGF- β type II receptor in FaDu cells.




Fig. 1. FaDu cells are defective in the induction of gene expression by TGF- $\beta 1$. Triplicate wells were cotransfected with the plasmid p800Luc containing the TGF- β response element from the PAI promoter (Abe, *et al.*, *Anal. Biochem.*, 216: 276–284, 1994) and the internal control pRL-TK (Promega) and treated with 1 ng/ml TGF- $\beta 1$ for 48 h. Luciferase activity was measured using the dual luciferase system (Promega), with luciferase activity from p800luc normalized to that obtained from pRL-TK. Similar results were obtained in two additional experiments. RLU, relative luciferase units.

Adam B. Glick
 Laboratory of Cellular Carcinogenesis and
 Tumor Promotion
 National Cancer Institute
 Bethesda, MD 20829